Key Segments:
By Drug Class
-
Combination Drugs
-
Beta-2 Agonists
-
Anticholinergic Agents
-
Corticosteroids
-
Monoclonal Antibodies
-
Others
By Indication
-
Asthma
-
COPD
-
Allergic Rhinitis
-
Pulmonary Arterial Hypertension
-
Cystic Fibrosis
-
Others
By Route of Administration
-
Inhaled
-
Oral
-
Injectable
-
Intranasal
-
Others
By Distribution Channel
-
Retail Pharmacies
-
Hospital Pharmacies
-
Other Channels
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Roche, Sanofi, Regeneron, Merck, Vertex, Cipla, Lupin, Grifols, Teva, Pfizer, Chiesi, Amgen, Amneal, Glenmark, and Viatris.
The main opportunities lie in acquiring clinical-stage respiratory biotechnology developers, and in expanding treatment of under-served indications such as bronchiectasis and pulmonary fibrosis.
The key growth factor is rising global prevalence of asthma and COPD, reinforced by expanding regulatory approval of novel biologic therapies for severe disease.
By drug class, the Combination Drugs segment dominated the market with approximately 27.00% share in 2025, reflecting prescriber preference for simplified multi-agent inhaler therapy.
North America dominated the market with approximately 38.00% share in 2025, supported by a large diagnosed patient population and a concentration of originator pharmaceutical companies.
